Fracture Risk After Initiation of Use of Canagliflozin
Authors: Hema Padmanabhan
Journal: Annals of Internal Medicine (2019)

Letters2 July 2019Fracture Risk After Initiation of Use of CanagliflozinHema Padmanabhan, MDHema Padmanabhan, MDNavicent Healthcare, Macon, Georgia (H.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0319 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Fralick and colleagues (1) conclude that canagliflozin is not associated with a higher risk for fracture than a glucagon-like peptide-1 (GLP-1) agonist in middle-aged patients with type 2 diabetes mellitus and an otherwise relatively low fracture risk. Their data may not provide a full picture of canagliflozin's effect on bones, thus making this conclusion less reliable.The patient population in their cohort study was relatively young, which reduces their risk for fracture. The large number of men in this study also may have affected the results. Postmenopausal women are at greater risk for bone loss and fracture ...References1. Fralick M, Kim SC, Schneeweiss S, et al. Fracture risk after initiation of use of canagliflozin. A cohort study. Ann Intern Med. 2019. [PMID: 30597484]. doi:10.7326/M18-0567 LinkGoogle Scholar2. Wolverton D, Blair MM. Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Am J Health Syst Pharm. 2017;74:1143-51. [PMID: 28743778] doi:10.2146/ajhp160319 CrossrefMedlineGoogle Scholar3. Reiss E, Canterbury JM, Bercovitz MA, et al. The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest. 1970;49:2146-9. [PMID: 5475987] CrossrefMedlineGoogle Scholar4. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. [PMID: 28605608] doi:10.1056/NEJMoa1611925 CrossrefMedlineGoogle Scholar5. Kahn SE, Zinman B, Lachin JM, et al; Diabetes Outcome Progression Trial (ADOPT) Study Group.. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-51. [PMID: 18223031] doi:10.2337/dc07-2270 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Navicent Healthcare, Macon, Georgia (H.P.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0319. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFracture Risk After Initiation of Use of Canagliflozin Michael Fralick , Seoyoung C. Kim , Sebastian Schneeweiss , Dae Kim , Donald A. Redelmeier , and Elisabetta Patorno Fracture Risk After Initiation of Use of Canagliflozin Michael Fralick , Seoyoung C. Kim , Sebastian Schneeweiss , Dae Kim , Donald A. Redelmeier , and Elisabetta Patorno Metrics 2 July 2019Volume 171, Issue 1Page: 79-80KeywordsBoneBone fractureBone resorptionGlomerular filtration rateOsteoporosisParathyroid hormonePhosphatesPhosphorusType 2 diabetesVitamin D ePublished: 2 July 2019 Issue Published: 2 July 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...